New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids

References

• PertweeRGEmerging strategies for exploiting cannabinoid receptor agonists as medicinesBr J Pharmacol2009156339741119226257
   PubMed Web of Science ®Google Scholar
• KreitzerACRegehrWGRetrograde signalling by endocannabinoidsCurr Opin Neurobiol20021232433012049940
   PubMed Web of Science ®Google Scholar
• AlgerBERetrograde signalling in the regulation of synaptic transmission: focus on endocannabinoidsProg Neurobiol20026824728612498988
   PubMed Web of Science ®Google Scholar
• BakerDPryceGCroxfordJLEndocannabinoids control spasticity in a multiple sclerosis modelFASEB J20011530030211156943
   PubMed Web of Science ®Google Scholar
• BakerDPryceGCroxfordJLCannabinoids control spasticity and tremor in a multiple sclerosis modelNature2000404848710716447
   PubMed Web of Science ®Google Scholar
• BerrenderoFSanchezACabranesAChanges in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosisSynapse20014119520211391780
   PubMed Web of Science ®Google Scholar
• BakerDPryceGThe endocannabinoid system and multiple sclerosisCurr Pharm Des200814232326233618781983
   PubMed Web of Science ®Google Scholar
• British Medical AssociationTherapeutic Uses Of CannabisAmsterdamHarwood Academic Publishers1997
   Google Scholar
• ConsroePMustyRReinJThe perceived effects of smoked Cannabis on patients with multiple sclerosisEur Neurol19973844489252798
   PubMed Web of Science ®Google Scholar
• HallWDDegenhardtLJCurrowDAllowing the medical use of CannabisMed J Aust2001175394011476203
   PubMed Web of Science ®Google Scholar
• SmithPFCannabinoids for the treatment of multiple sclerosis: No smoke without fire?Exp Rev Neurotherapeutics20033327357
   PubMedGoogle Scholar
• SmithPFMedicinal Cannabis extracts for the treatment of multiple sclerosisCurr Opin Investig Drugs20045727730
   PubMedGoogle Scholar
• KillesteinJHoogervorstELJReifMSafety, tolerability and efficacy of orally administered cannabinoids in MSNeurol20025814041407
   PubMed Web of Science ®Google Scholar
• ZajicekJFoxPSandersHCannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trialLancet20033621517152614615106
   PubMed Web of Science ®Google Scholar
• ZajicekJPSandersHPWrightDECannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-upJ Neurol Neurosurg Psychiat2005761664166916291891
   PubMed Web of Science ®Google Scholar
• WadeDTRobsonPHouseHA preliminary controlled study to determine whether whole-plant Cannabis extracts can improve intractable neurogenic symptomsClin Rehabil200317212912617376
   PubMed Web of Science ®Google Scholar
• WadeDTMakelaPRobsonPDo Cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patientsMultiple Sclerosis20041043444115327042
   PubMed Web of Science ®Google Scholar
• KillesteinJPolmanCThe therapeutic value of cannabinoids in MS: real or imaginary?Multiple Sclerosis20041033934015327026
   PubMed Web of Science ®Google Scholar
• VaneyCHeinzel-GutenbrunnerMJobinPEfficacy, safety and tolerability of an orally administered Cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover studyMultiple Sclerosis20041041742415327040
   PubMed Web of Science ®Google Scholar
• BradyCMDasGuptaRDaltonCAn open-label pilot study of Cannabis based extracts for bladder dysfunction in advanced multiple sclerosisMultiple Sclerosis20041042543315327041
   PubMed Web of Science ®Google Scholar
• CollinCDaviesPMutibokoIKSativex Spasticity in MS Study GroupRandomised controlled trial of Cannabis-based medicine in spasticity caused by multiple sclerosisEur J Neurol20071429029617355549
   PubMed Web of Science ®Google Scholar
• WisselJHaydnTMullerJLow dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related painJ Neurol2006253101337134116988792
   PubMed Web of Science ®Google Scholar
• HagenbachULuzSGhafoorNThe treatment of spasticity with Delta-9-tetrahydrocannabinol in persons with spinal cord injurySpinal Cord200745855156217043680
   PubMed Web of Science ®Google Scholar
• ShakespeareDTBoggildMYoungCAnti-spasticity agents for multiple sclerosisCochrane Database Systematic Reviews20004CD001332
   Google Scholar
• SmithPFEvaluation of Sativex (GW-1000)IDdb3 Current Drugs Databasehttp://www.iddb3.com2004119
   Google Scholar
• SmithPFSativex (GW-1000)Current Opinion in Investigational Drugs2004574875415298072
   PubMedGoogle Scholar
• WadeDTMakelaPMHouseHLong-term use of a Cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosisMultiple Sclerosis200612563964517086911
   PubMed Web of Science ®Google Scholar
• AragonaMOnestiETomassiniVPsychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo-controlled, crossover studyClin Neuropharmacol2009321414718978501
   PubMed Web of Science ®Google Scholar
• CampbellFATramerMRCarollDAre cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic reviewBrit Med J2001323131611440935
   PubMed Web of Science ®Google Scholar
• TramerMRCarollDCampbellFACannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic reviewBrit Med J2001323162111440936
   PubMed Web of Science ®Google Scholar
• FergussonDPoultonRSmithPFCannabis and psychosisBrit Med J200633217217516424500
   PubMed Web of Science ®Google Scholar
• MooreTHMZammitSLingford-HughesACannabis use and risk of psychotic or affective mental health outcomes: A systematic reviewLancet200737031932817662880
   PubMed Web of Science ®Google Scholar
• FriedPAWatksinsonBDifferential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuanaNeurotoxicol Teratol20012342143011711244
   PubMed Web of Science ®Google Scholar
• FriedPASmithAMA literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive functionNeurotoxicol Teratol20012311111274871
   PubMed Web of Science ®Google Scholar
• FriedPAWatkinsonBGrayRDifferential effects on cognitive functioning in 13- to 16 year-olds prenatally exposed to cigarettes and marihuanaNeurotoxicol Teratol20032542743612798960
   PubMed Web of Science ®Google Scholar
• GoldschmidtLRichardsonGACorneliusMDPrenatal marijuana and alcohol exposure and academic achievement at age 10Neurotoxicol Teratol20042652153215203174
   PubMed Web of Science ®Google Scholar
• GoldschmidtLDayNLRichardsonGAEffects of prenatal marijuana exposure on child behavior problems at age 10Neurotoxicol Teratol20002232533610840176
   PubMed Web of Science ®Google Scholar
• SmithAMFriedPAHoganMJEffects of prenatal marijuana on response inhibition: an fMRI study of young adultsNeurotoxicol Teratol20042653354215203175
   PubMed Web of Science ®Google Scholar
• Newsham-WestDDarlingtonCLSmithPFPotent effects of a selective cannabinoid receptor agonist on some medial vestibular nucleus neuronsEur J Pharmacol1998348R1R29650841
   PubMed Web of Science ®Google Scholar
• AshtonJCZhengYLiuPImmunohistochemical characterization and localization of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and effects of unilateral vestibular deafferentationBrain Res20041021266273
   Google Scholar
• PryceGBakerDControl of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptorsBr J Pharmacol2007150451952517220914
   PubMed Web of Science ®Google Scholar
• WhalleyBJWilkinsonJDWilliamsonEMA novel component of Cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitroNeurosci Letts2004365586315234473
   PubMed Web of Science ®Google Scholar
• WilkinsonJDWhalleyBJBakerDMedicinal Cannabis: Is delta-9-tetrahydrocannabinol necessary for all its effects?J Pharm Pharmacol2003551687169414738597
   PubMed Web of Science ®Google Scholar
• LienauFSFüllgrafHMoserAWhy do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis?Eur J Neurol2007141162116917880571
   PubMed Web of Science ®Google Scholar